Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial - Wikidata - wikimedia - TriplyDB

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

http://www.wikidata.org/entity/Q35125893

about

Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma New criteria for response assessment: role of minimal residual disease in multiple myeloma A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Immunomodulatory drugs in multiple myeloma.Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Thalidomide and its analogues in the treatment of Multiple Myeloma Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.Multiple myeloma in the marrow: pathogenesis and treatments.A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma Bortezomib combination therapy in multiple myeloma.Sequential or combination therapy for multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.Current approaches to the initial treatment of symptomatic multiple myeloma.Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma.Emerging stem cell therapies: treatment, safety, and biology.A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.Bortezomib for the treatment of multiple myeloma.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

P2860

Q21285161-42D8C78B-27D0-4D30-A321-6BE48BAD8009 Q27027512-E9967DFA-167D-4EDC-9013-645AD32BDAA7 Q33399844-D431B7A0-CF54-4476-901E-9F9E9FA0A417 Q33404007-5BB54B88-8950-4727-83AA-7F3D750DEA47 Q33405532-016BCE6D-6EA8-4D60-A8A0-022A238C12D4 Q33410297-DB5092E2-7362-4347-A8FA-D430863139A6 Q33412684-A8FFAB74-D22A-42E4-968E-47D52682EE40 Q34253548-94BD708C-C5A6-4268-B56F-24EFD728701C Q34325722-317681E3-2E8A-4958-A17B-662B5AA98546 Q35569350-B74881D1-3091-491E-A057-593791265000 Q35868171-17971AED-098E-4267-8001-C968436ACC01 Q36012111-DC59CBB7-43C6-4F6C-878C-27F7409657D0 Q36444523-6F93EEA2-BEB7-46EC-856D-99EE1F3A8A1B Q36502820-5ED16E77-9A17-4E5E-A2F9-DC6AA0E1FD09 Q36541807-85A59198-1BFE-4590-A86E-EC3B55134DCB Q36592788-03229799-DC35-446C-A2A5-5217E1BD7F36 Q36725401-2B815C2C-6C80-42B7-B9DF-6EBE5AA43A14 Q37027114-2AEF6671-5525-489B-B35B-CE1D4E55E6B4 Q38021041-ADD8579F-17D3-4B4C-9E25-BD95403D4430 Q38059253-A68BEAA7-3C00-4406-A3AD-DA0AC997C56A Q38096055-A773E18B-2212-4740-B10B-F68371086CA4 Q38413040-E47D9B76-5BD1-4509-B658-83A8BF73EE66 Q38545607-005AF70D-949B-4298-803D-27BC9710D87F Q38738098-DB7D1DD1-331B-478C-BEE8-01DDF7711951 Q38833538-C46911D2-3C82-44FA-939D-FA7215990836 Q39524467-40ECCEE1-7129-4851-B8B0-93D6595572E7 Q41819491-4E68FBDE-15D9-473E-B13F-5ADB4B5A38FD Q41849927-170A5BAA-9202-4957-B4A1-0941327C0DAB Q41955327-A267E3F2-E142-4D3F-ACBC-BA82C30C9986 Q42132657-9CE77F1D-053D-4F1F-AEDF-3526B25530DA Q42272171-8932A8C9-FD1F-4795-88CA-030325495D9C Q44469916-195D157C-D124-4D8F-8F3E-C8821443D9D0 Q46147631-74CA851A-8248-4615-B84F-3E0B67CD9466 Q47604607-832BEF38-96B7-448B-9AB4-1DABA37EA67D Q53522981-65F1A694-A3ED-4D6C-8E82-3AF2063E40F4

P2860

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

http://www.wikidata.org/entity/Q35125893

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial

@ast

Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial

@en

type

label

Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial

@ast

Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial

@en

prefLabel

Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial

@ast

Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial

@en

P1433

Q35125893-3A73937E-A418-401F-AF46-7ECFFB338AC5

P1476

Q35125893-FF4628B1-A0E6-4E65-B376-413E1C98DA9F

P2093

Q35125893-0AF8C8C0-AC3B-4938-953B-151C295B6667

Q35125893-0FC2EB6D-332C-4DFF-853E-E48F1B9318D5

Q35125893-0FCE40CA-E579-4E4C-86B3-24969A024BAE

Q35125893-1AE4B27F-A8B0-40F1-A740-F228663B2B91

Q35125893-303C6E1B-8852-41A7-9B11-2D03411B4C64

Q35125893-53D737AF-9CA6-4F29-859D-2EEC155F4774

Q35125893-699424C6-DD5E-40B9-8038-AF2DE25AD78C

Q35125893-873E3EA9-88AD-44CC-B926-D73786FB3DB1

Q35125893-8C6AAAB4-D853-487E-83F7-87B5C4BB2870

Q35125893-94362548-B744-4A76-8265-F8307F8F1E77

P2860

Q35125893-009AE46A-B34E-4783-A7B8-E1A3B8CED4B1

Q35125893-0935501C-4601-4AFA-8432-98A7D5EBECB7

Q35125893-0B9B489C-123E-4CF9-AFED-3F05775D354C

Q35125893-2A8E0627-EAEB-49E6-9CCC-986A0C6FBF99

Q35125893-4912A92C-08CD-4B26-A3A2-CC317981E746

Q35125893-52A71FA1-EF2D-44A8-B967-191AF58785A4

Q35125893-54455DAB-D925-4D50-8BFB-6022CE9B128D

Q35125893-611E45B0-55F5-4E6A-B761-5FDA19286BD3

Q35125893-6C2B5286-D3C1-4530-9554-442EAE03DCA9

Q35125893-741B9242-DC80-403F-9442-3B75556385CB

P304

Q35125893-D351E0CF-AB76-4B54-A004-6363D1C275A7

P31

Q35125893-34043272-060B-4867-B1F4-7CCD2CCF5D74

P356

Q35125893-805E8FF6-AA2C-4639-A8FC-F2FD20ABEC15

P407

Q35125893-0AC55E91-2E83-41A9-A91A-9EFBDEE6ADAE

P433

Q35125893-7B87B0E2-5DF9-4438-B2E9-74F5726A0D2E

P478

Q35125893-673ABA43-E4A0-427A-8AB7-C178C85CB1BC

P50

Q35125893-0FF7EF23-234D-4D47-8159-0FCA5594AD63

Q35125893-1F259456-B12A-4F30-B46F-024F93C1A8C5

Q35125893-3FB04EC2-9EED-44E8-AB8A-C22B33724A1F

Q35125893-FD1A4AA3-287C-4567-A483-DF8F91939AFD

P577

Q35125893-EC35C97D-2FF6-429A-9512-96570E1FC2DC

P5875

Q35125893-742A3F48-9AFF-4F20-AC59-D82D5C321590

P698

Q35125893-D92AE060-B526-4EC5-BBF1-45C61D8F27FC

P921

Q35125893-0FBA4890-8B63-49C8-8386-51598855FC41

Q35125893-1352B9DC-3E82-4DE5-AE04-315B705F53D2

Q35125893-2F40B7FA-0F7C-4258-96AB-3EC714CA93E3

P932

Q35125893-1AF16D4A-94B6-4F8E-802A-D505C18586BD

P356

BLOOD-2011-02-334755

P1433

P1476

Lenalidomide, bortezomib, pegy ...... loma Research Consortium trial

@en

P2093

Andrzej J Jakubowiak

http://www.w3.org/2001/XMLSchema#string

Colleen K Harvey

http://www.w3.org/2001/XMLSchema#string

Craig C Hofmeister

http://www.w3.org/2001/XMLSchema#string

Craig L Tendler

http://www.w3.org/2001/XMLSchema#string

Dixie-Lee Esseltine

http://www.w3.org/2001/XMLSchema#string

Donna E Reece

http://www.w3.org/2001/XMLSchema#string

Erica L Campagnaro

http://www.w3.org/2001/XMLSchema#string

Jacob P Laubach

http://www.w3.org/2001/XMLSchema#string

Jennifer C Barrickman

http://www.w3.org/2001/XMLSchema#string

Kent A Griffith

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

International uniform response criteria for multiple myeloma.

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

New drugs for myeloma.

Bortezomib in the front-line treatment of multiple myeloma.

P304

535-543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-02-334755

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2011-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51150701

http://www.w3.org/2001/XMLSchema#string

P698

21596852

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

P932

3142898

http://www.w3.org/2001/XMLSchema#string